Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Mesenchymal Stem Cell Preparations in the Treatment of Autism Spectrum Disorder
TCTR20260427019Phase 2Not yet recruiting
- Sponsor
- Zibo 148 Hospital
- Start
- Mar 2026
- Countries
- 1
01
Overview
Phase 2 trial in Autism Spectrum Disorder (ASD), sponsored by Zibo 148 Hospital. Planned start Mar 2026; status: not yet recruiting.
02
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on TCTR20260427019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260427019.